Plant cells as pharmaceutical factories

Research output: Contribution to journalArticleScientificpeer-review

33 Citations (Scopus)

Abstract

Molecules derived from plants make up a sizeable proportion of the drugs currently available on the market. These include a number of secondary metabolite compounds the monetary value of which is very high. New pharmaceuticals often originate in nature. Approximately 50% of new drug entities against cancer or microbial infections are derived from plants or micro-organisms. However, these compounds are structurally often too complex to be economically manufactured by chemical synthesis, and frequently isolation from naturally grown or cultivated plants is not a sustainable option. Therefore the biotechnological production of high-value plant secondary metabolites in cultivated cells is potentially an attractive alternative. Compared to microbial systems eukaryotic organisms such as plants are far more complex, and our understanding of the metabolic pathways in plants and their regulation at the systems level has been rather poor until recently. However, metabolic engineering including advanced multigene transformation techniques and state-of-art metabolomics platforms has given us entirely new tools to exploit plants as Green Factories. Single step engineering may be successful on occasion but in complex pathways, intermediate gene interventions most often do not affect the end product accumulation. In this review we discuss recent developments towards elucidation of complex plant biosynthetic pathways and the production of a number of highvalue pharmaceuticals including paclitaxel, tropane, morphine and terpenoid indole alkaloids in plants and cell cultures.
Original languageEnglish
Pages (from-to)5640-5660
Number of pages20
JournalCurrent Pharmaceutical Design
Volume19
Issue number31
DOIs
Publication statusPublished - 2013
MoE publication typeA1 Journal article-refereed

Fingerprint

Plant Cells
Pharmaceutical Preparations
Secologanin Tryptamine Alkaloids
Tropanes
Viridiplantae
Metabolic Engineering
Metabolomics
Biosynthetic Pathways
Paclitaxel
Metabolic Networks and Pathways
Morphine
Cell Culture Techniques
Infection
Genes
Neoplasms

Keywords

  • genetic engineering
  • medicinal plants
  • natural products
  • pharmaceuticals
  • plant cell culture
  • secondary metabolites

Cite this

@article{e31c92974a5d4aa59ee68d786b5fdaa1,
title = "Plant cells as pharmaceutical factories",
abstract = "Molecules derived from plants make up a sizeable proportion of the drugs currently available on the market. These include a number of secondary metabolite compounds the monetary value of which is very high. New pharmaceuticals often originate in nature. Approximately 50{\%} of new drug entities against cancer or microbial infections are derived from plants or micro-organisms. However, these compounds are structurally often too complex to be economically manufactured by chemical synthesis, and frequently isolation from naturally grown or cultivated plants is not a sustainable option. Therefore the biotechnological production of high-value plant secondary metabolites in cultivated cells is potentially an attractive alternative. Compared to microbial systems eukaryotic organisms such as plants are far more complex, and our understanding of the metabolic pathways in plants and their regulation at the systems level has been rather poor until recently. However, metabolic engineering including advanced multigene transformation techniques and state-of-art metabolomics platforms has given us entirely new tools to exploit plants as Green Factories. Single step engineering may be successful on occasion but in complex pathways, intermediate gene interventions most often do not affect the end product accumulation. In this review we discuss recent developments towards elucidation of complex plant biosynthetic pathways and the production of a number of highvalue pharmaceuticals including paclitaxel, tropane, morphine and terpenoid indole alkaloids in plants and cell cultures.",
keywords = "genetic engineering, medicinal plants, natural products, pharmaceuticals, plant cell culture, secondary metabolites",
author = "Heiko Rischer and Suvi H{\"a}kkinen and Anneli Ritala and Tuulikki Sepp{\"a}nen-Laakso and B. Miralpeix and T. Capell and P. Christou and Kirsi-Marja Oksman-Caldentey",
year = "2013",
doi = "10.2174/1381612811319310017",
language = "English",
volume = "19",
pages = "5640--5660",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers",
number = "31",

}

Plant cells as pharmaceutical factories. / Rischer, Heiko; Häkkinen, Suvi; Ritala, Anneli; Seppänen-Laakso, Tuulikki; Miralpeix, B.; Capell, T.; Christou, P.; Oksman-Caldentey, Kirsi-Marja.

In: Current Pharmaceutical Design, Vol. 19, No. 31, 2013, p. 5640-5660.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Plant cells as pharmaceutical factories

AU - Rischer, Heiko

AU - Häkkinen, Suvi

AU - Ritala, Anneli

AU - Seppänen-Laakso, Tuulikki

AU - Miralpeix, B.

AU - Capell, T.

AU - Christou, P.

AU - Oksman-Caldentey, Kirsi-Marja

PY - 2013

Y1 - 2013

N2 - Molecules derived from plants make up a sizeable proportion of the drugs currently available on the market. These include a number of secondary metabolite compounds the monetary value of which is very high. New pharmaceuticals often originate in nature. Approximately 50% of new drug entities against cancer or microbial infections are derived from plants or micro-organisms. However, these compounds are structurally often too complex to be economically manufactured by chemical synthesis, and frequently isolation from naturally grown or cultivated plants is not a sustainable option. Therefore the biotechnological production of high-value plant secondary metabolites in cultivated cells is potentially an attractive alternative. Compared to microbial systems eukaryotic organisms such as plants are far more complex, and our understanding of the metabolic pathways in plants and their regulation at the systems level has been rather poor until recently. However, metabolic engineering including advanced multigene transformation techniques and state-of-art metabolomics platforms has given us entirely new tools to exploit plants as Green Factories. Single step engineering may be successful on occasion but in complex pathways, intermediate gene interventions most often do not affect the end product accumulation. In this review we discuss recent developments towards elucidation of complex plant biosynthetic pathways and the production of a number of highvalue pharmaceuticals including paclitaxel, tropane, morphine and terpenoid indole alkaloids in plants and cell cultures.

AB - Molecules derived from plants make up a sizeable proportion of the drugs currently available on the market. These include a number of secondary metabolite compounds the monetary value of which is very high. New pharmaceuticals often originate in nature. Approximately 50% of new drug entities against cancer or microbial infections are derived from plants or micro-organisms. However, these compounds are structurally often too complex to be economically manufactured by chemical synthesis, and frequently isolation from naturally grown or cultivated plants is not a sustainable option. Therefore the biotechnological production of high-value plant secondary metabolites in cultivated cells is potentially an attractive alternative. Compared to microbial systems eukaryotic organisms such as plants are far more complex, and our understanding of the metabolic pathways in plants and their regulation at the systems level has been rather poor until recently. However, metabolic engineering including advanced multigene transformation techniques and state-of-art metabolomics platforms has given us entirely new tools to exploit plants as Green Factories. Single step engineering may be successful on occasion but in complex pathways, intermediate gene interventions most often do not affect the end product accumulation. In this review we discuss recent developments towards elucidation of complex plant biosynthetic pathways and the production of a number of highvalue pharmaceuticals including paclitaxel, tropane, morphine and terpenoid indole alkaloids in plants and cell cultures.

KW - genetic engineering

KW - medicinal plants

KW - natural products

KW - pharmaceuticals

KW - plant cell culture

KW - secondary metabolites

U2 - 10.2174/1381612811319310017

DO - 10.2174/1381612811319310017

M3 - Article

VL - 19

SP - 5640

EP - 5660

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 31

ER -